Safety, Tolerability, PK and efficacy of AZD1152 in Patients with Relapsed Acute Myeloid Leukemia
Study identifier:D1531C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase I/II, open label, multi-centre study to assess the safety, tolerability, pharmacokinetics and efficacy of AZD1152 in patients with acute myeloid leukaemia.
Medical condition
Myeloid Leukemia
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD1152
Sex
All
Actual Enrollment
65
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 May 2006
Primary Completion Date: 01 Oct 2009
Study Completion Date: 01 Apr 2010
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Paul Stockman
AstraZeneca
